Trial Profile

A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Renal cell carcinoma
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KEYNOTE-029
Sponsors Merck Sharp & Dohme Corp.

01 Jul 2021 Results (At data cutoff February 18, 2019; n=102 ) from cohort 1C, evaluating standard dose pembrolizumab with two other alternative ipilimumab regimens in advanced melanoma, published in the Clinical Cancer Research
05 Apr 2021 Status changed from active, no longer recruiting to completed.
15 Feb 2021 Planned End Date changed from 8 Feb 2021 to 11 Mar 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com